Week 4 on 0.5mg Ozempic: what the data actually shows

What did @liyanail999 actually say?

Honestly, not much that we can work with clinically. The transcript is a loop of "I don't know if I'm going to go to the airport" repeated three times, with no coherent health claim attached. The caption tells us more: "4 неделя на 0,5" translates from Russian as "week 4 on 0.5" with the hashtag "оземпик" (Ozempic). So the framing is a week-four update on 0.5mg semaglutide, but the spoken content doesn't deliver any specific claim about weight loss, side effects, or outcomes.

This is a common format on Russian-language TikTok: a lifestyle check-in that implies progress without stating it. The creator appears to be documenting a personal semaglutide journey, which is genuinely useful social signal for others considering GLP-1 therapy. But the verbal content here is either corrupted, mislabeled, or simply off-topic. We can't fact-check what wasn't said.

Does the science back this up?

Since the only verifiable claim is the dosing context, 0.5mg semaglutide at week four, let's look at what the evidence actually says about that stage of treatment. Week four is typically the tail end of the initial titration dose before escalation.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) used a titration protocol starting at 0.25mg for the first four weeks, moving to 0.5mg for weeks five through eight, before reaching the 1mg and eventually 2.4mg maintenance doses used in Wegovy. At week four, patients are still in a low-dose window where weight loss effects are modest but side effects, particularly nausea and GI discomfort, are often at their most disruptive.

A 2022 analysis in Obesity (Kushner et al.) confirmed that GI adverse events peak during titration and taper with dose stabilization. So someone at week four on 0.5mg is exactly where the clinical literature predicts they might feel uncertain, unsettled, or distracted. Whether that explains the incoherent transcript is anyone's guess.

What did they get wrong (or right)?

There's nothing to correct because there's nothing substantive claimed. The transcript contains no health misinformation, no dangerous dosing advice, no false equivalency between compounded and brand-name semaglutide. It also contains no useful health information at all.

What the creator got right, implicitly, is simply existing as a data point. Real-world documentation of GLP-1 journeys, even messy or incoherent ones, contributes to the growing body of patient-reported experience. A 2023 paper in JAMA Network Open (Butsch et al.) noted that patient narratives on social media often capture side effect profiles that clinical trials underreport, including cognitive fog, fatigue, and motivational shifts. Could "I don't know if I'm going to go to the airport" be a window into semaglutide-related cognitive or motivational effects? Possibly. But that's speculation, not a fact-checkable claim.

The format itself, a weekly update series, is low-risk from a misinformation standpoint as long as future videos don't start promoting specific doses, comparing compounded versions to brand-name products, or attributing disease resolution to the medication.

What should you actually know?

Week four on 0.5mg semaglutide is a real clinical moment, even if this video doesn't articulate it clearly. Patients at this stage are often navigating the peak of titration side effects while seeing minimal weight change. That gap between expectation and experience drives a lot of early discontinuation.

The SUSTAIN trials (Aroda et al., 2017, Diabetes Care) showed that adherence in the first eight weeks is a strong predictor of long-term outcome. Dropping off because week four felt hard is one of the most common and most avoidable failure points in GLP-1 therapy. If you're watching videos like this one looking for reassurance that week four confusion is normal, the answer is: yes, probably. But a TikTok is not a substitute for talking to the prescriber who put you on the medication.

One more thing worth flagging: Ozempic is approved for type 2 diabetes management. Wegovy, the higher-dose semaglutide formulation, is the approved weight loss version. Anyone using Ozempic off-label for weight loss should be doing so under direct medical supervision, not calibrating expectations based on social media timelines.